Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects With Carcinoid Syndrome
Sponsor: Crinetics Pharmaceuticals Inc.
Listed as NCT05361668, this PHASE2 trial focuses on Carcinoid and Carcinoid Intestine Tumor and remains ongoing. Sponsored by Crinetics Pharmaceuticals Inc., it has been updated 15 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 10 earlier versions
-
Dec 2023 — Mar 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Jul 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE2
First recorded
Apr 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Crinetics Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .